processing....
The American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) indicates that sinus node dysfunction (SND) is most often related to age-dependent progressive fibrosis of the sinus nodal tissue and surrounding atrial myocardium leading to abnormalities of sinus node and atrial impulse formation and propagation and will therefore result in various bradycardic or pause-related syndromes. [1,2] SND is thus characterized by dysfunction of the sinoatrial (SA) node that is often associated with senescence of the node and surrounding atrial myocardium. [3,4] Although the term "sick sinus syndrome" (SSS) was first used to describe the sluggish return of SA nodal activity following electrical cardioversion, it is now commonly used to describe the inability of the SA node to generate a heart rate commensurate with the physiologic needs of an individual.
A conglomeration of electrocardiogram (ECG) abnormalities represent manifestation of SND, including [3,5,6]:
Sinus bradycardia
Sinus pause
Sinus arrest
SA nodal exit block
Inadequate heart rate response to physiologic demands during activity (chronotropic incompetence)
When SND is associated with symptoms such as dizziness or syncope, SSS is a more clinically representative term. However, SND and SSS are often used interchangeably.
SND occurs as a result of disorders in automaticity, conduction, or both of the SA node. [9] Local cardiac pathology, systemic diseases that involve the heart, and medications or toxins can all be responsible for abnormal SA node function and may result in SND. [9,10,11] SN fibrosis is the most common cause of SND.
Abnormal automaticity, or sinus arrest, refers to a failure of sinus impulse generation. Abnormal conduction, or SA delay or block, is a failure of impulse transmission. In such cases, the sinus impulse is generated normally, but it is abnormally conducted to the neighboring atrial tissue. Both abnormal automaticity and abnormal conduction may result from one of several different mechanisms, including fibrosis, atherosclerosis, and inflammatory or infiltrative myocardial processes.
The most common cause of SND/sick sinus syndrome (SSS) is the replacement of sinus node (SN) tissue by fibrous tissue, which may be accompanied by degeneration and fibrosis of other parts of the conduction system as well, including the atrioventricular (AV) node. The transitional junction between the SN and atrial tissue may also be involved, and there may be degeneration of the nerve ganglia.
A number of medications and toxins can depress sinus node function, resulting in symptoms and electrocardiographic (ECG) changes consistent with SND. The most commonly used prescription medications that alter myocardial conduction and may potentially result in SND include:
Beta blockers
Non-dihydropyridine calcium channel blockers (eg, diltiazem, verapamil)
Digoxin
Antiarrhythmic medications
Ivabradine
Acetylcholinesterase inhibitors (eg, donepezil, rivastigmine) used in the treatment of Alzheimer disease
Parasympathomimetic agents
Sympatholytic drugs (eg, methyldopa, clonidine)
Lithium
Poisoning by grayanotoxin, which is produced by some plants (eg,Rhododendron species) and found in certain varieties of honey, has been associated with depressed SN function
Although rare in children, when SND presents in this population, it is most often seen in those with congenital and acquired heart disease, particularly after corrective cardiac surgery. Familial SSS is rare, with mutations in the cardiac sodium channel geneSCN5A [12,13] and theHCN4 gene [14] (thought to contribute to the SN pacemaker current) responsible for some familial cases.
In a series of 30 children and young adults (age range: 3 days to 25 years) with SND, 22 had significant cardiac disease, and 13 developed SND after cardiac surgery. [15] The causes of SND were inappropriate sinus bradycardia, sinus arrest, and SA exit block. [15]
In a study of 10 children from 7 families with familial SSS, in which genomic DNA encoding the alpha subunit of the cardiac sodium channel was screened for mutations, compound heterozygous nucleotide changes were identified in 5 children from 3 families, but not in any of over 75 control subjects. [12]
In a series of 38 patients with clinical evidence of Brugada syndrome, 4 hadSCN5A mutations. Of these 4 patients, 3 had SND with multiple affected family members. However, mutations inSCN5A are not pathognomonic for SND, as differentSCN5A mutations are associated with other cardiac abnormalities including Brugada syndrome, congenital long QT syndrome type 3, familial atrioventricular (AV) block, and familial dilated cardiomyopathy with conduction defects and susceptibility to atrial fibrillation (AF). [13]
Infiltrative diseases
The SA node may be affected by infiltrative disease, such as amyloidosis, sarcoidosis, scleroderma, hemochromatosis, and rarely tumor.
Inflammatory diseases
Rheumatic fever, pericarditis, diphtheria, Chagas disease, and other disorders may depress SA nodal function.
SA nodal artery disease
The SN is perfused by branches of the right coronary artery in 55-60% of cases, and by the left circumflex artery in the remaining 40-45%. Stenosis of the SA nodal artery may occur due to atherosclerosis or inflammatory processes, resulting in ischemia; the latter may also occur with embolic events. Approximately 5% of patients with myocardial infarction (MI) (usually inferior wall MI) show SND that tends to be reversible. [16]
Genetic mutations
Mutations inHCN4 can produce both symptomatic and asymptomatic SND, as illustrated by numerous reports of sinus bradycardia in family members with such mutations. [17]
Trauma
Cardiac trauma may affect either the SA node directly or its blood supply.
Miscellaneous
Other disorders that can cause SND include hypothyroidism, hypothermia, hypoxia, and muscular dystrophies. Some infections (eg, leptospirosis, trichinosis,Salmonella typhi infection) are associated with relative sinus bradycardia; however, these usually do not result in permanent SND. [18]
In addition, SND is seen in children with congenital and acquired heart disease, particularly after corrective surgery. The cause of SND in these children is likely related to the underlying structural heart disease and surgical trauma to the SN and/or SN artery.
Emery-Dreifuss muscular dystrophy is an X-linked muscle disorder associated with SND and AV conduction defects. If AV conduction defects are present, sudden cardiac death may result unless the condition is treated with permanent pacing. Males and females may be affected with equal frequency.
Sinus venosus atrial septal defect (ASD),Ebstein anomaly, and heterotaxy syndromes, particularly left atrial isomerism, can also lead to SND.
Gradual loss of sinus rhythm occurs after the Mustard, Senning, and all varieties of the Fontan operation. This is thought to be secondary to direct injury to the SN during surgery and also due to later, chronic hemodynamic abnormalities. Paroxysmal atrial tachycardias are frequently associated with SND, and loss of sinus rhythm appears to increase the risk of sudden death. Patients with transposition of the great arteries now undergo the arterial switch operation, which avoids the extensive atrial suture lines that lead to SN damage.
SND was described in 15% of patients who had undergone the Ross operation for aortic valve disease or complex left-sided heart disease, 2.6 to 11 years earlier. [19] Other arrhythmias, such as complete AV block and ventricular tachycardia, were present as well after the Ross operation.
When repairing ASDs, especially sinus venosus ASDs, SND frequently occurs because of the proximity of the defect with SN tissue.
Other surgically related causes of SND include the following:
Patients who have undergone surgery for endocardial cushion defects (ECDs) may later develop SND
SND may be caused by a Blalock-Hanlon atrial septectomy
SND may occur after repair ofpartial anomalous pulmonary venous return (PAPVR) or total anomalous pulmonary venous return (TAPVR)
Cannulation of the superior vena cava (SVC), usually performed for cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO), may damage SN tissue
Ischemic cardiac arrest may cause SND
Rheumatic fever is another cause of SND. Such dysfunction may also result from central nervous system (CNS) disease, which is usually secondary to increased intracranial pressure with a subsequent increase in the parasympathetic tone.
Endocrine-metabolic diseases (hypothyroidism and hypothermia) and electrolyte imbalances (hypokalemia and hypocalcemia) are other conditions that can contribute to SND.
A study by Sunaga et al involving 202 subjects indicated that in patients with persistent AF, those with low-amplitude fibrillatory waves and a large left atrial volume index are at an increased risk for the appearance of concealed SND after catheter ablation has restored sinus rhythm. [20]
The sinoatrial (SA) node is innervated by the parasympathetic and the sympathetic nervous systems; the balance between these systems controls the pacemaker rate. Parasympathetic input via the vagus nerves decreases the SA nodal pacemaker and is the dominant input at rest, whereas sympathetic nerve input, as well as the adrenal medullary release of catecholamines, increases the sinus rate during exercise and stress.
The sinus node (SN) is a subepicardial structure normally located in the right atrial wall near the superior vena cava entrance on the upper end of the sulcus terminalis. It is formed by a cluster of cells capable of spontaneous depolarization. Normally, these pacemaker cells depolarize at faster rates than any other latent cardiac pacemaker cell inside the heart. Therefore, a healthy SN directs the rate at which the heart beats. Electrical impulses generated in the SN must then be conducted outside the SN in order to depolarize the rest of the heart.
SN activity is regulated by the autonomic nervous system. For example, parasympathetic stimulation causes sinus bradycardia, sinus pauses, or sinoatrial exit block. These actions decrease SN automaticity, thereby decreasing the heart rate.
Sympathetic stimulation, however, increases the slope of phase 4 spontaneous depolarizations. This increases the automaticity of the SN, thereby increasing the heart rate. Blood supply to the SN is provided by the right coronary artery in most cases.
SND involves abnormalities in SN impulse formation and propagation, which are often accompanied by similar abnormalities in the atrium and in the conduction system of the heart. Together, these abnormalities may result in inappropriately slow ventricular rates and long pauses at rest or during various stresses. When SND is mild, patients are usually asymptomatic. As SND becomes more severe, patients may develop symptoms due to organ hypoperfusion and pulse irregularity. Such symptoms include the following:
Fatigue
Dizziness
Confusion
Fall
Syncope
Angina
Heart failure symptoms and palpitations
The natural history of SND typically involves intermittent and/or progressive cardiac rhythm disorders, which have been associated with higher rates of other cardiovascular events and higher mortality. There is a tendency for the rhythm disturbances associated with SND to evolve over time, along with a higher likelihood of thromboembolic events and other cardiovascular events.
For many patients with SND, there are variable, and often long, periods of normal SN function. However, once present, in due course, SND progresses in most patients, accompanied by a greater likelihood of developing atrial tachyarrhythmias. However, the time course of disease progression is difficult to predict; hence, most patients with symptomatic SND are treated earlier in an attempt to alleviate symptoms.
As noted, SND usually progresses over time. In a study of 52 patients with SND and sinus bradycardia associated with SA block or sinus arrest, it took an average of 13 years (range, 7-29 years) for progression to total sinus arrest and an escape rhythm. [21]
The incidence of atrial arrhythmias and conduction disturbances occurs more frequently over time, which may be due in part to a progressive pathologic process that affects the entire atrium and other parts of the heart. In a study comprising 213 patients with a history of symptomatic SND who were treated with atrial pacing and followed for a median of 5 years, 7% developed atrial fibrillation and 8.5% developed high-grade atrioventricular block. [22]
Patients with SND, especially those with tachycardia-bradycardia, are at higher risk for thromboembolic events—even after pacemaker implantation. Asymptomatic episodes of atrial fibrillation resulting in thromboembolic events may contribute to cardiovascular events following pacemaker implantation.
The epidemiology of SND is difficult to study, given its nature and varying manifestations, including nonspecific symptoms and electrocardiographic (ECG) findings. It is estimated that the incidence of SND in the United States is approximately 1 in 600 cardiac patients older than 65 years. [23] Due to its relationship with advanced age, SND is more prevalent in countries where citizens have a longer life expectancy.
Symptomatic patients are generally older, in seventh or eighth decade of life, with frequent comorbidities. Only a few epidemiologic studies have been published.
A pooled analysis of 20,572 patients from two large epidemiology studies (the Atherosclerosis Risk in Communities [ARIC] and Cardiovascular Health Study [CHS] trials) who were followed for an average of 17 years, 291 incident cases of sick sinus syndrome (SSS) were noted, yielding an incidence rate of 0.8 cases per 1000 person-years. [4] Although several variables were associated with the development of SSS (eg, higher body mass index, hypertension, prior cardiovascular event), advancing age was the most significant risk factor for SSS (hazard ratio 1.73 for each additional 5 years of age (95% confidence interval: 1.47-2.05). [4]
In major trials of pacing in this disorder, the median or mean age of the patients with SND was 73 to 76 years. Men and women appear equally affected and, although less common, SND/SSS can also occur in younger adults and children. [24,25,26]
The prognosis of patients with SND is dependent on the underlying associated condition. The incidence of sudden cardiac death in patients with SND is low. [24] Pacemaker therapy does not appear to affect survival in patients with SND. [27,28,29]
Patients with tachy-brady syndrome have a worse prognosis than do patients with isolated SND. The overall prognosis in patients with SND and additional systemic ventricular dysfunction (eg, numerous postoperative Mustard and Fontan patients) depends on their underlying ventricular dysfunction or degree ofcongestive heart failure (CHF).
In patients who have undergone a Fontan surgery and developed SND, endocardial atrial leads can be implanted relatively safely and can permit low-energy thresholds for as long as 5 years after implantation. [30]
The relationship between SND and mortality is difficult to clearly understand, as many individuals with SND have preexisting comorbidities (eg, hypertension, diabetes mellitus, atrial fibrillation) that are known to increase all-cause mortality. [31]
The complications of SND include the following:
Sudden cardiac death
Syncope
Thromboembolic events, including stroke
CHF
Atrial tachyarrhythmias
About 50% of patients with SND develop tachy-brady syndrome over a lifetime; such patients have a higher risk of stroke and death. However, the incidence of sudden death owing directly to SND is extremely low. [24]
[Guideline] Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart Rhythm. 2018 Oct 31.[QxMD MEDLINE Link].[Full Text].
Brooks M. New ACC/AHA/HRS guidance on bradycardia, conduction disorders. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/904455. November 6, 2018; Accessed: November 15, 2018.
[Guideline] Epstein AE, DiMarco JP, Ellenbogen KA, et al, for the American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.J Am Coll Cardiol. 2013 Jan 22. 61(3):e6-75.[QxMD MEDLINE Link].
Jensen PN, Gronroos NN, Chen LY, et al. Incidence of and risk factors for sick sinus syndrome in the general population.J Am Coll Cardiol. 2014 Aug 12. 64(6):531-8.[QxMD MEDLINE Link].[Full Text].
Ferrer MI. The sick sinus syndrome in atrial disease.JAMA. 1968 Oct 14. 206(3):645-6.[QxMD MEDLINE Link].
[Guideline] Epstein AE, DiMarco JP, Ellenbogen KA, et al, for the ACC/AHA Task Force on Practice Guidelines, American Association for Thoracic Surgery, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.J Am Coll Cardiol. 2008 May 27. 51(21):e1-62.[QxMD MEDLINE Link].
Zhao J, Liu T, Li G. Relationship between two arrhythmias: sinus node dysfunction and atrial fibrillation.Arch Med Res. 2014 May. 45(4):351-5.[QxMD MEDLINE Link].
[Guideline] Glikson M, Burri H, Abdin A, et al. European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society.Europace. 2025 Mar 28. 27 (4):[QxMD MEDLINE Link].[Full Text].
Choudhury M, Boyett MR, Morris GM. Biology of the sinus node and its disease.Arrhythm Electrophysiol Rev. 2015 May. 4(1):28-34.[QxMD MEDLINE Link].
Birchfield RI, Menefee EE, Bryant GD. Disease of the sinoatrial node associated with bradycardia, asystole, syncope, and paroxysmal atrial fibrillation.Circulation. 1957 Jul. 16(1):20-6.[QxMD MEDLINE Link].
Rubenstein JJ, Schulman CL, Yurchak PM, DeSanctis RW. Clinical spectrum of the sick sinus syndrome.Circulation. 1972 Jul. 46(1):5-13.[QxMD MEDLINE Link].
Benson DW, Wang DW, Dyment M, et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A).J Clin Invest. 2003 Oct. 112(7):1019-28.[QxMD MEDLINE Link].
Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations.J Am Coll Cardiol. 2005 Dec 6. 46(11):2100-6.[QxMD MEDLINE Link].
Ishikawa T, Ohno S, Murakami T, et al. Sick sinus syndrome with HCN4 mutations shows early onset and frequent association with atrial fibrillation and left ventricular noncompaction.Heart Rhythm. 2017 May. 14(5):717-24.[QxMD MEDLINE Link].
Yabek SM, Jarmakani JM. Sinus node dysfunction in children, adolescents, and young adults.Pediatrics. 1978 Apr. 61(4):593-8.[QxMD MEDLINE Link].
Alboni P, Baggioni GF, Scarfo S, et al. Role of sinus node artery disease in sick sinus syndrome in inferior wall acute myocardial infarction.Am J Cardiol. 1991 Jun 1. 67(15):1180-4.[QxMD MEDLINE Link].
Nof E, Luria D, Brass D, et al. Point mutation in the HCN4 cardiac ion channel pore affecting synthesis, trafficking, and functional expression is associated with familial asymptomatic sinus bradycardia.Circulation. 2007 Jul 31. 116(5):463-70.[QxMD MEDLINE Link].
Cunha BA. The diagnostic significance of relative bradycardia in infectious disease.Clin Microbiol Infect. 2000 Dec. 6(12):633-4.[QxMD MEDLINE Link].
Pasquali SK, Marino BS, Kaltman JR, et al. Rhythm and conduction disturbances at midterm follow-up after the ross procedure in infants, children, and young adults.Ann Thorac Surg. 2008 Jun. 85(6):2072-8.[QxMD MEDLINE Link].
Sunaga A, Masuda M, Kanda T, et al. A low fibrillatory wave amplitude predicts sinus node dysfunction after catheter ablation in patients with persistent atrial fibrillation.J Interv Card Electrophysiol. 2015 Sep. 43(3):253-61.[QxMD MEDLINE Link].
Lien WP, Lee YS, Chang FZ, Lee SY, Chen CM, Tsai HC. The sick sinus syndrome: natural history of dysfunction of the sinoatrial node.Chest. 1977 Nov. 72 (5):628-34.[QxMD MEDLINE Link].
Brandt J, Anderson H, Fahraeus T, Schuller H. Natural history of sinus node disease treated with atrial pacing in 213 patients: implications for selection of stimulation mode.J Am Coll Cardiol. 1992 Sep. 20(3):633-9.[QxMD MEDLINE Link].
Rodriguez RD, Schocken DD. Update on sick sinus syndrome, a cardiac disorder of aging.Geriatrics. 1990 Jan. 45(1):26-30, 33-6.[QxMD MEDLINE Link].
Lamas GA, Lee KL, Sweeney MO, et al, for the Mode Selection Trial in Sinus-Node Dysfunction. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction.N Engl J Med. 2002 Jun 13. 346(24):1854-62.[QxMD MEDLINE Link].
Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome.Lancet. 1994 Dec 3. 344(8936):1523-8.[QxMD MEDLINE Link].
Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators.N Engl J Med. 2000 May 11. 342(19):1385-91.[QxMD MEDLINE Link].
Menozzi C, Brignole M, Alboni P, et al. The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome.Am J Cardiol. 1998 Nov 15. 82(10):1205-9.[QxMD MEDLINE Link].
Simon AB, Janz N. Symptomatic bradyarrhythmias in the adult: natural history following ventricular pacemaker implantation.Pacing Clin Electrophysiol. 1982 May. 5(3):372-83.[QxMD MEDLINE Link].
Alt E, Volker R, Wirtzfeld A, Ulm K. Survival and follow-up after pacemaker implantation: a comparison of patients with sick sinus syndrome, complete heart block, and atrial fibrillation.Pacing Clin Electrophysiol. 1985 Nov. 8(6):849-55.[QxMD MEDLINE Link].
Shah MJ, Nehgme R, Carboni M, Murphy JD. Endocardial atrial pacing lead implantation and midterm follow-up in young patients with sinus node dysfunction after the fontan procedure.Pacing Clin Electrophysiol. 2004 Jul. 27(7):949-54.[QxMD MEDLINE Link].
[Guideline] Zipes DP, DiMarco JP, Gillette PC, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology.J Am Coll Cardiol. 1995 Aug. 26 (2):555-73.[QxMD MEDLINE Link].
Josephson ME, ed. Sinus node function.Clinical Cardiac Electrophysiology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
[Guideline] Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology.J Am Coll Cardiol. 1999 Sep. 34(3):912-48.[QxMD MEDLINE Link].
Katritsis D, Camm AJ. Chronotropic incompetence: a proposal for definition and diagnosis.Br Heart J. 1993 Nov. 70(5):400-2.[QxMD MEDLINE Link].
[Guideline] Shah MJ, Silka MJ, Silva JNA, et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Developed in collaboration with and endorsed by the HRS, the ACC, the AHA, and the AEPC. Endorsed by the APHRS, the IHRS, and the LAHRS.JACC Clin Electrophysiol. 2021 Nov. 7 (11):1437-72.[QxMD MEDLINE Link].[Full Text].
[Guideline] Brignole M, Auricchio A, Baron-Esquivias G, et al, for the ESC Committee for Practice Guidelines (CPG). 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).Eur Heart J. 2013 Aug. 34(29):2281-329.[QxMD MEDLINE Link].
Rosenqvist M, Obel IW. Atrial pacing and the risk for AV block: is there a time for change in attitude?.Pacing Clin Electrophysiol. 1989 Jan. 12(1 pt 1):97-101.[QxMD MEDLINE Link].
Nielsen JC, Thomsen PE, Hojberg S, et al, for the DANPACE Investigators. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome.Eur Heart J. 2011 Mar. 32(6):686-96.[QxMD MEDLINE Link].
Chen S, Wang Z, Kiuchi MG, et al. Cardiac pacing strategies and post-implantation risk of atrial fibrillation and heart failure events in sinus node dysfunction patients: a collaborative analysis of over 6000 patients.Clin Res Cardiol. 2016 Aug. 105(8):687-98.[QxMD MEDLINE Link].
Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease.N Engl J Med. 2007 Sep 6. 357(10):1000-8.[QxMD MEDLINE Link].
Yu CM, Chan JY, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction.N Engl J Med. 2009 Nov 26. 361(22):2123-34.[QxMD MEDLINE Link].
Lamas GA, Knight JD, Sweeney MO, et al. Impact of rate-modulated pacing on quality of life and exercise capacity--evidence from the Advanced Elements of Pacing Randomized Controlled Trial (ADEPT).Heart Rhythm. 2007 Sep. 4(9):1125-32.[QxMD MEDLINE Link].
[Guideline] Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.J Am Coll Cardiol. 2016 Sep 27. 68(13):1476-88.[QxMD MEDLINE Link].
Bharat K Kantharia, MD, FRCP, FAHA, FACC, FESC, FHRS Clinical Professor of Medicine, Icahn School of Medicine at Mount Sinai; Cardiac Electrophysiologist, Mount Sinai Health System, New York-Presbyterian Healthcare System, Montefiore Medical Center, Lennox Hill Hospital
Bharat K Kantharia, MD, FRCP, FAHA, FACC, FESC, FHRS is a member of the following medical societies:American College of Cardiology,American Heart Association,Cardiac Electrophysiology Society,European Cardiac Arrhythmia Society,European Society of Cardiology,Heart Rhythm Society,Medical Society of the State of New York, Royal College of Physicians of Edinburgh,Royal College of Physicians of Ireland, Royal College of Physicians of London,Royal Society of Medicine,Texas Medical Association
Disclosure: Nothing to disclose.
Arti N Shah, MD, MS, FACC, FACP, CEPS-AC, CEDS Assistant Professor of Medicine, Mount Sinai School of Medicine; Director of Electrophysiology, Elmhurst Hospital Center and Queens Hospital Center
Arti N Shah, MD, MS, FACC, FACP, CEPS-AC, CEDS is a member of the following medical societies: American Association of Cardiologists of Indian Origin,American College of Cardiology,American College of Physicians,American Heart Association,Cardiac Electrophysiology Society, European Heart Rhythm Society,European Society of Cardiology,Heart Rhythm Society,New York Academy of Medicine
Disclosure: Nothing to disclose.
Arun Chutani, MD Senior Registrar, Nair Hospital, Topiwala National Medical College, India
Disclosure: Nothing to disclose.
Surendra K Chutani, MD, DM, FACC, FHRS, CEPS-AC, CCDS Fellow, Department of Cardiology, Mount Sinai St Luke's Hospital Center
Surendra K Chutani, MD, DM, FACC, FHRS, CEPS-AC, CCDS is a member of the following medical societies:American College of Cardiology, Asia Pacific Heart Rhythm Society,Association of Physicians of India, Cardiology Society of India, European Heart Rhythm Society,Heart Rhythm Society, Heart Rhythm Society of India
Disclosure: Nothing to disclose.
Mikhael F El-Chami, MD Associate Professor, Department of Medicine, Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine
Mikhael F El-Chami, MD is a member of the following medical societies:Alpha Omega Alpha,American College of Cardiology,American Heart Association,Heart Rhythm Society
Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Medtronic; Boston Scientific, Biotronik<br/>Received research grants (as part of Multicenter studies) from Medtronic and Boston Scientific.
Yasir Batres, MD Physician, Division of Cardiology, University of California, Davis, Medical Center
Yasir Batres, MD is a member of the following medical societies:American College of Cardiology
Disclosure: Nothing to disclose.
Stuart Berger, MD Professor of Pediatrics, Division of Cardiology, Medical College of Wisconsin; Chief of Pediatric Cardiology, Medical Director of Pediatric Heart Transplant Program, Medical Director of The Heart Center, Children's Hospital of Wisconsin
Stuart Berger, MD is a member of the following medical societies:American Academy of Pediatrics,American College of Cardiology,American College of Chest Physicians,American Heart Association, andSociety for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.
Alan D Forker, MD Professor of Medicine, University of Missouri at Kansas City School of Medicine; Director, Outpatient Lipid Diabetes Research, MidAmerica Heart Institute of St Luke's Hospital
Alan D Forker, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association , American Society of Hypertension, and Phi Beta Kappa
Disclosure: Nothing to disclose.
M Silvana Horenstein, MD Assistant Professor, Department of Pediatrics, University of Texas Medical School at Houston; Medical Doctor Consultant, Legacy Department, Best Doctors, Inc
M Silvana Horenstein, MD is a member of the following medical societies:American Academy of Pediatrics,American College of Cardiology, andAmerican Medical Association
Disclosure: Nothing to disclose.
Peter P Karpawich, MD Professor of Pediatric Medicine, Department of Pediatrics (Cardiology), Wayne State University School of Medicine; Director, Cardiac Electrophysiology and Pacemaker Services, Children's Hospital of Michigan
Peter P Karpawich, MD is a member of the following medical societies:American Academy of Pediatrics,American College of Cardiology,American Heart Association,Heart Rhythm Society,Michigan State Medical Society, andPediatric Electrophysiology Society
Disclosure: Nothing to disclose.
Adrian W Messerli, MD Consulting Staff, Cardiology Associates of Kentucky
Disclosure: Nothing to disclose.
John W Moore, MD, MPH Professor of Clinical Pediatrics, Section of Pediatric Cardiology, Department of Pediatrics, University of California San Diego School of Medicine; Director of Cardiology, Rady Children's Hospital
John W Moore, MD, MPH is a member of the following medical societies:American Academy of Pediatrics,American College of Cardiology, andSociety for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.
Brian Olshansky, MD Professor of Medicine, Department of Internal Medicine, University of Iowa College of Medicine
Brian Olshansky, MD is a member of the following medical societies:American Autonomic Society,American College of Cardiology,American College of Chest Physicians,American College of Physicians,American College of Sports Medicine, American Federation for Clinical Research,American Heart Association,Cardiac Electrophysiology Society,Heart Rhythm Society, andNew York Academy of Sciences
Disclosure: Guidant/Boston Scientific Honoraria Speaking and teaching; Medtronic Honoraria Speaking and teaching; Guidant/Boston Scientific Consulting fee Consulting; Novartis Honoraria Speaking and teaching; Novartis Consulting fee Consulting
Justin D Pearlman, MD, PhD, ME, MA Director of Advanced Cardiovascular Imaging, Professor of Medicine, Professor of Radiology, Adjunct Professor, Thayer Bioengineering and Computer Science, Dartmouth-Hitchcock Medical Center
Justin D Pearlman, MD, PhD, ME, MA is a member of the following medical societies:American College of Cardiology,American College of Physicians,American Federation for Medical Research,International Society for Magnetic Resonance in Medicine, andRadiological Society of North America
Disclosure: Nothing to disclose.
Paul M Seib, MD Associate Professor of Pediatrics, University of Arkansas for Medical Sciences; Medical Director, Cardiac Catheterization Laboratory, Co-Medical Director, Cardiovascular Intensive Care Unit, Arkansas Children's Hospital
Paul M Seib, MD is a member of the following medical societies:American Academy of Pediatrics,American College of Cardiology,American Heart Association,Arkansas Medical Society,International Society for Heart and Lung Transplantation, andSociety for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Medscape Salary Employment
Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Nothing to disclose.